US/UK/Canada

Share

Quotes

We are very excited to enter into this collaboration with a development partner with such broad experience and expertise in the field as well as direct market knowledge and legacy. Wider patient access to naloxone is one of the goals of many health authorities throughout the world and we believe KL-00514 can provide broad access and relative ease of use for a very competitive cost.
Dr. Scott Boyer, CEO, Klaria
Collaborating on the development of KL-00514, a product designed to specifically address opioid overdose, is another concrete step we are taking to address a serious public health issue crisis Canadians are facing. Prescription opioid medicines remain a safe and effective treatment option for patients who are appropriately selected and monitored; however, these medicines have risks. It is our goal to provide access to life-saving treatments that support the combined efforts of regulators and governments of all levels to make treatments for intentional or accidental overdose as broadly available as possible.
Dr. Craig Landau, President and CEO, Purdue Pharma (Canada)
Investing in drug development to bring value to patients has always been an integral part of Purdue Canada’s contributions to the healthcare system and to Canadian patients. In the case of KL-00514, subject to successful clinical development and subsequent approval by Health Canada, those who use diverted medications and suffer from accidental or intentional overdose may also benefit.
Dr. Craig Landau, President and CEO, Purdue Pharma (Canada)
The granting of the patent in Mexico completes the patent protection we have been seeking for all of North America. Mexico joins Canada and of course the US in the expanding list of areas in which our products will enjoy patent protection. In fact, the US patent will extend into 2029
Dr. Scott Boyer, CEO of Klaria Pharma Holding AB
”We have chosen to start with one of the most interesting projects in our portfolio – KL-00119. All of our projects have three important steps in their development and now KL-00119 have passed the first – to assure a functional formulation. The next critical milestone will be to perform the clinical trial and this is where both Recipharm and CTC will be extremely important collaborators”
Scott Boyer, CEO, Klaria Pharma Holding
”Both Recipharm and CTC have a huge amount of experience in their respective areas and we have complete faith in their ability to execute their parts of our project with high quality, to expected costs and to the agreed timelines”
Scott Boyer, CEO, Klaria Pharma Holding
The ambition is to create world-leading products in the area of acute pain management
Dr. Scott Boyer, CEO, Klaria
Beyond the pain management we also want to give the patient back a sense of control. For patients that are affected by recurrent and severe bouts of pain, the sense of control is often just as valuable as the actual pain management.
Dr. Scott Boyer, CEO, Klaria
By combining our unique drug delivery platform with proven drugs, we will be able to offer a medication the will allow patients never to have to use a nasal spray, swallow a tablet or to inject themselves. These are exactly the type of products patients, healthcare professionals and regulatory authorities are asking for
Dr. Scott Boyer, CEO, Klaria
Pick a time period -
Tags ( Active)
There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe